vs
Liberty Global Ltd.（LBTYA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Liberty Global Ltd.的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs -237.0%，领先249.7%），Liberty Global Ltd.同比增速更快（187.2% vs 5.9%），Liberty Global Ltd.自由现金流更多（$193.3M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -20.4%）
自由全球有限公司是一家英荷美合资的跨国电信企业，注册地位于百慕大，在伦敦、阿姆斯特丹和丹佛均设有总部。公司旗下拥有英国自由全球控股有限公司、荷兰自由全球有限公司及美国自由全球公司三大主体，其中英国主体为上市实体。企业由自由媒体国际业务部与UnitedGlobalCom于2005年合并成立，在全球电信服务领域拥有深厚的行业积累。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LBTYA vs RVTY — 直观对比
营收规模更大
LBTYA
是对方的1.6倍
$772.1M
营收增速更快
LBTYA
高出181.3%
5.9%
净利率更高
RVTY
高出249.7%
-237.0%
自由现金流更多
LBTYA
多$31.5M
$161.8M
两年增速更快
RVTY
近两年复合增速
-20.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $-2.9B | $98.4M |
| 毛利率 | 66.8% | — |
| 营业利润率 | -8.6% | 14.5% |
| 净利率 | -237.0% | 12.7% |
| 营收同比 | 187.2% | 5.9% |
| 净利润同比 | -230.0% | 3.9% |
| 每股收益（稀释后） | $-8.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBTYARVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $-1.4B | $729.4M | ||
| Q3 24 | $1.9B | $684.0M | ||
| Q2 24 | $1.9B | $691.7M | ||
| Q1 24 | $1.9B | $649.9M |
净利润LBTYARVTY
| Q4 25 | $-2.9B | $98.4M | ||
| Q3 25 | $-90.7M | $46.7M | ||
| Q2 25 | $-2.8B | $53.9M | ||
| Q1 25 | $-1.3B | $42.2M | ||
| Q4 24 | $2.2B | $94.6M | ||
| Q3 24 | $-1.4B | $94.4M | ||
| Q2 24 | $268.1M | $55.4M | ||
| Q1 24 | $510.0M | $26.0M |
毛利率LBTYARVTY
| Q4 25 | 66.8% | — | ||
| Q3 25 | 67.5% | 53.6% | ||
| Q2 25 | 63.3% | 54.5% | ||
| Q1 25 | 65.6% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 69.4% | 56.3% | ||
| Q2 24 | 68.5% | 55.7% | ||
| Q1 24 | 65.4% | 54.6% |
营业利润率LBTYARVTY
| Q4 25 | -8.6% | 14.5% | ||
| Q3 25 | -0.7% | 11.7% | ||
| Q2 25 | 2.3% | 12.6% | ||
| Q1 25 | 5.2% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 5.2% | 14.3% | ||
| Q2 24 | 1.0% | 12.4% | ||
| Q1 24 | 1.2% | 6.8% |
净利率LBTYARVTY
| Q4 25 | -237.0% | 12.7% | ||
| Q3 25 | -7.5% | 6.7% | ||
| Q2 25 | -220.1% | 7.5% | ||
| Q1 25 | -114.2% | 6.4% | ||
| Q4 24 | -158.9% | 13.0% | ||
| Q3 24 | -74.1% | 13.8% | ||
| Q2 24 | 14.3% | 8.0% | ||
| Q1 24 | 26.2% | 4.0% |
每股收益（稀释后）LBTYARVTY
| Q4 25 | $-8.66 | $0.86 | ||
| Q3 25 | $-0.27 | $0.40 | ||
| Q2 25 | $-8.09 | $0.46 | ||
| Q1 25 | $-3.84 | $0.35 | ||
| Q4 24 | $6.15 | $0.77 | ||
| Q3 24 | $-3.95 | $0.77 | ||
| Q2 24 | $0.71 | $0.45 | ||
| Q1 24 | $1.32 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.2B | $919.9M |
| 总债务越低越好 | $7.8B | — |
| 股东权益账面价值 | $9.7B | $7.3B |
| 总资产 | $22.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资LBTYARVTY
| Q4 25 | $2.2B | $919.9M | ||
| Q3 25 | $1.7B | $931.4M | ||
| Q2 25 | $3.1B | $991.8M | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.2B | $1.2B | ||
| Q3 24 | $3.3B | $1.2B | ||
| Q2 24 | $3.2B | $2.0B | ||
| Q1 24 | $2.8B | $1.7B |
总债务LBTYARVTY
| Q4 25 | $7.8B | — | ||
| Q3 25 | $7.8B | — | ||
| Q2 25 | $7.8B | — | ||
| Q1 25 | $8.2B | — | ||
| Q4 24 | $8.2B | — | ||
| Q3 24 | $14.9B | — | ||
| Q2 24 | $14.7B | — | ||
| Q1 24 | $14.8B | — |
股东权益LBTYARVTY
| Q4 25 | $9.7B | $7.3B | ||
| Q3 25 | $12.7B | $7.4B | ||
| Q2 25 | $13.0B | $7.6B | ||
| Q1 25 | $12.6B | $7.6B | ||
| Q4 24 | $12.4B | $7.7B | ||
| Q3 24 | $18.7B | $7.9B | ||
| Q2 24 | $18.3B | $7.9B | ||
| Q1 24 | $18.4B | $7.8B |
总资产LBTYARVTY
| Q4 25 | $22.6B | $12.2B | ||
| Q3 25 | $25.4B | $12.1B | ||
| Q2 25 | $27.2B | $12.4B | ||
| Q1 25 | $26.0B | $12.4B | ||
| Q4 24 | $25.4B | $12.4B | ||
| Q3 24 | $41.8B | $12.8B | ||
| Q2 24 | $40.8B | $13.4B | ||
| Q1 24 | $40.6B | $13.4B |
负债/权益比LBTYARVTY
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.80× | — | ||
| Q2 24 | 0.80× | — | ||
| Q1 24 | 0.80× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $630.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $193.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.7% | 21.0% |
| 资本支出强度资本支出/营收 | 35.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-132.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LBTYARVTY
| Q4 25 | $630.9M | $182.0M | ||
| Q3 25 | $301.8M | $138.5M | ||
| Q2 25 | $149.2M | $134.3M | ||
| Q1 25 | $129.2M | $128.2M | ||
| Q4 24 | $791.6M | $174.2M | ||
| Q3 24 | $449.5M | $147.9M | ||
| Q2 24 | $546.1M | $158.6M | ||
| Q1 24 | $245.7M | $147.6M |
自由现金流LBTYARVTY
| Q4 25 | $193.3M | $161.8M | ||
| Q3 25 | $-41.1M | $120.0M | ||
| Q2 25 | $-170.1M | $115.5M | ||
| Q1 25 | $-114.1M | $112.2M | ||
| Q4 24 | $712.9M | $149.8M | ||
| Q3 24 | $102.4M | $125.6M | ||
| Q2 24 | $256.8M | $136.6M | ||
| Q1 24 | $-105.1M | $129.7M |
自由现金流率LBTYARVTY
| Q4 25 | 15.7% | 21.0% | ||
| Q3 25 | -3.4% | 17.2% | ||
| Q2 25 | -13.4% | 16.0% | ||
| Q1 25 | -9.7% | 16.9% | ||
| Q4 24 | -50.5% | 20.5% | ||
| Q3 24 | 5.3% | 18.4% | ||
| Q2 24 | 13.7% | 19.7% | ||
| Q1 24 | -5.4% | 20.0% |
资本支出强度LBTYARVTY
| Q4 25 | 35.5% | 2.6% | ||
| Q3 25 | 28.4% | 2.6% | ||
| Q2 25 | 25.2% | 2.6% | ||
| Q1 25 | 20.8% | 2.4% | ||
| Q4 24 | -5.6% | 3.4% | ||
| Q3 24 | 17.9% | 3.3% | ||
| Q2 24 | 15.4% | 3.2% | ||
| Q1 24 | 18.0% | 2.7% |
现金转化率LBTYARVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 0.35× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 2.04× | 2.87× | ||
| Q1 24 | 0.48× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBTYA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
